决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.
我们的研究提供了NKTCL异质性的高分辨率分子图谱,为患者分层和未来治疗开发的潜在途径提供了见解。
肿瘤细胞异质性及其与免疫微环境的相互作用在自然杀伤/T细胞淋巴瘤(NKTCL)的进展和治疗疗效中发挥关键作用。我们对63份样本进行单细胞RNA测序分析,整合空间转录组学、批量转录组学、蛋白质组学和代谢组学,以剖析肿瘤间和肿瘤内异质性。鉴定出四种元程序(MP),包括MP1(免疫反应型)、MP2(增殖型)、MP3(炎症型)和MP4(代谢型),每种均与不同的分子和免疫特征相关。MP1表现出免疫耗竭的肿瘤微环境和高程序性死亡配体1表达,提示对免疫检查点阻断的潜在应答。MP2显示免疫荒漠表型,HDAC2和MKI67表达升高,表明表观遗传调控在肿瘤增殖中的作用。MP3以髓系主导的肿瘤微环境、JAK/STAT通路激活和侵袭性临床病程为特征。MP4表现出独特的氨基酸代谢谱和富集的第三淋巴结构。总体而言,我们的研究提供了NKTCL异质性的高分辨率分子图谱,为患者分层和未来治疗开发的潜在途径提供了见解。
Tumor cell heterogeneity and interactions with the immune microenvironment play a key role in the progression and therapeutic efficacy of natural killer/T-cell lymphoma (NKTCL). We perform single-cell RNA sequencing analysis of 63 samples, integrating spatial transcriptomics, bulk transcriptomics, proteomics, and metabolomics to dissect inter- and intra-tumoral heterogeneity. Four meta-programs (MP) are identified, including MP1 (immune-responsive), MP2 (proliferative), MP3 (inflammatory), and MP4 (metabolic), each linked to distinct molecular and immune features. MP1 exhibits an immune-exhausted tumor microenvironment and high programmed death-ligand 1 expression, suggesting a potential response to immune checkpoint blockade. MP2 shows an immune-desert phenotype with elevated HDAC2 and MKI67 expression, indicating epigenetic regulation in tumor proliferation. MP3 is characterized by a myeloid-dominant tumor microenvironment, JAK/STAT pathway activation, and an aggressive clinical course. MP4 exhibits a distinct amino acid metabolic profile and enriched tertiary lymphoid structures. Collectively, our study provides a high-resolution molecular atlas of NKTCL heterogeneity, offering insights into patient stratification and potential avenues for future therapeutic development.
MEMBER ACCOUNT
登录成功会直接打开下一页。